OA
OrbiMed Asia
OrbiMed Asia is a Series A to Series C stage investment firm. It has made 5 investments. Their most common stage is series-a (40% of deals). Average disclosed round size is $23.1M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
DW
David Wang
Senior Managing Director
AB
Ankesh Bhansali
Managing Director, Private Equity
AS
Arun Sadhanandham
Managing Director, Private Equity
DZ
Daniel Zhou
Managing Director
JW
Jonathan Wang
Managing Director
WC
W. Carter Neild
Managing Director
JW
Jonathan W.
Founder, scientist, investor
YL
Yifu Liu
Investment Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| EEpigenic Therapeutics | Series A | $32M | Aug 2023 |
| ZZentera Therapeutics | Series A | — | Jan 2020 |
| BBonovo Orthopedics | Series C | $10M | Dec 2010 |
| UUquifa | Unknown | $42.5M | — |
| WWhale Imaging | Unknown | $8M | — |
Top Co-Investors
Last updated: 14 September 2026